Anzeige
❌
Mehr »
Dienstag, 17.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
IM

WKN: A41XT7 | ISIN: KYG4790P1037 | Ticker: O15
Tradegate
16.11.26 | 16:30
4,220 Euro
-1,86 % -0,080
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
INSILICO MEDICINE CAYMAN TOPCO Chart 1 Jahr
5-Tage-Chart
INSILICO MEDICINE CAYMAN TOPCO 5-Tage-Chart
RealtimeGeldBriefZeit
4,0804,24016.11.
4,1404,18016.11.

Aktuelle News zur INSILICO MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoINSILICO Repurchases 300,000 Shares Last Fri for Over HKD11.2 million4
FrINSILICO (03696): NEXT DAY DISCLOSURE RETURN1
FrINSILICO Enters Strategic AI Drug Development Partnership With Luoxin Pharmaceutical10
FrINSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE AND LUOXIN PHARMACEUTICALS ENTER INTO STRATEGIC COLLABORATION ON AI-POWERED DRUG DISCOVERY ...3
10.11.INSILICO Spends HKD7.562 Million to Buy Back 199,000 Shares on Mon25
INSILICO MEDICINE Aktie jetzt für 0€ handeln
09.11.INSILICO Repurchased 400,000 Shares Last Fri for HKD15.0059 million8
06.11.INSILICO (03696): NEXT DAY DISCLOSURE RETURN4
03.11.INSILICO (03696): DISCLOSEABLE TRANSACTION PARTICIPATION IN THE ESTABLISHMENT OF AN INVESTMENT FUND6
30.10.INSILICO Plans Share Buyback of Up to HKD500M10
30.10.INSILICO (03696): VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE9
29.10.INSILICO (03696): GRANT OF RESTRICTED SHARE UNITS4
27.10.INSILICO Releases Preliminary Data From Phase I Human Clinical Trial of ISM63319
27.10.INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE REPORTS PRELIMINARY POSITIVE FIRST-IN-HUMAN CLINICAL TRIAL DATA FOR ISM6331 DESIGNED USING ...13
26.10.Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026222CAMBRIDGE, Mass., Oct. 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI-driven drug discovery company, today announced promising first-in-human Phase...
► Artikel lesen
20.10.Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering An undisclosed Milestone Payment2.491Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement. Insilico reached the first...
► Artikel lesen
20.10.INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE TRIGGERS A MILESTONE PAYMENT IN AI-DRIVEN R&D COLLABORATION WITH SERVIER FOR ACHIEVING EARLY ...5
13.10.INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE NOMINATES PERIPHERAL-RESTRICTED VAV1 MOLECULAR GLUE DEGRADER FOR POTENTIAL TREATMENT OF AUTOIMMUNE ...15
07.10.Crypto.com integrates Insilico Terminal to deliver professional-grade trading tools10
30.09.INSILICO (03696): VOLUNTARY ANNOUNCEMENT INSILICO MEDICINE NOMINATES NEXT-GENERATION SMALL MOLECULE GIPR ANTAGONIST FOR POTENTIAL INTERVENTION OF OBESITY ...30
21.09.Insilico Jumps After Signing Deal to Develop Biology AI Models Worth Tens of Millions of US Dollars7
1 2 3 4 5 Weiter >>
96 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2